Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of allogeneic bone marrow transplantation in treating patients who have multiple myeloma, chronic phase chronic myelogenous leukemia, or agnogenic myeloid metaplasia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide

Criteria

DISEASE CHARACTERISTICS:

• Cytologically proven disease of one of the following types with transfusion-dependent anemia or thrombocytopenia (less than 50,000/mm^3):

• Multiple myeloma

• Agnogenic myeloid metaplasia

• Chronic myelogenous leukemia in first or second chronic phase

• Philadelphia chromosome with BCR gene rearrangement

• Suitable sibling bone marrow donor available

PATIENT CHARACTERISTICS:

Age:

• 15 to physiologic 55

Performance status:

• ECOG 0 or 1

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin no greater than 2.0 mg/dL

• SGOT less than 2 times normal

• Alkaline phosphatase less than 2 times normal

Renal:

• Creatinine less than 2 mg/dL

Cardiovascular:

• Ejection fraction normal by MUGA

• No acute myocardial infarction within the past 6 months

• No active angina pectoris

• No active congestive heart failure

Pulmonary:

• FEV greater than 50% predicted

• DLCO at least 50%

Other:

• HIV negative

• No active infection

• No concurrent organ damage or medical problems that would preclude therapy

PRIOR CONCURRENT THERAPY:

• Not specified